Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $8.7152W HIGH $11.42
Volume
20.28 M
Value Traded
34.85 M
Short % Float
0.5%
+3.91%Week
-1.8%1 Month
-17.05%3 Month
-5.4%6 Month
+19.1%5 Year
+19.1%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
40.73 B
EPS (TTM)
0.49
P/E Ratio
19.07
Ent. Value
50.77 B
Total Shares
4.43 B
Float Shares
4.40 B
Insiders
0.00%
Institutions
13.48%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
HLN Catalyst Timeline
Dated clinical, regulatory and corporate events for Haleon plc
Past FDA Catalysts and PDUFA Decisions
How HLN actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2020-02-28 | Advil Dual Action With Acetaminophen (acetaminophen) | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D39 / 100
Pipeline Score
$717M
Pipeline Value
$59.1B
Commercial Value
Fair Value
Valuation Signal
6
Drugs Scored
0.1x
rNPV / MCap
Top 41%
Mid Cap(rank 270 of 658)
Percentile Rank
Haleon plc faces pipeline headwinds (39/100), with $847M risk-adjusted pipeline value, led by ENO Lime in Indigestion Acid (Phase 3).
Commercial products (revenue basis: trailing 4 quarters of total revenue (20-F and 6-K), converted from GBP to USD, to Jun 2026) Revenue $15.0B x 4.0 = $59.1B
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ENO Lime Small moleculeCompletedNCT07140341 | Indigestion Acid | Phase 3 | COMPLETED | 40 | Sep 6, 2025 |
Clinical Trial Results
Readouts, endpoints and source filings for every HLN program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| John SmithCEO | Buy | 50,000 150,000 held | $45.50 | 01/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in HLN
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in HLN for Q2 2026. | ||||
HLN Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-05-21 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How HLN ranks across every disease it competes in
Competitive Position is a premium feature
See how HLN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialHLN News
HLNCentrum Launches Newly Reformulated Adults 50+ Complete Multivitamin with Clinically Shown Cognitive Benefits
Haleon has launched the Centrum Adults 50+ Complete Multivitamin, reformulated to meet the nutritional needs of older adults. This new multivitamin includes essential vitamins and minerals that support immune health, energy metabolism, and cognitive function. Backed by clinical trials, it aims to enhance memory and brain health, reinforcing Centrum's commitment to evidence-based innovation.
Read more →HLNHaleon Appoints Richard Manso as US Chief Marketing Officer to Advance Data-driven, Consumer-centric Marketing in Delivering Better Everyday Health
Haleon has appointed Richard Manso as the US Chief Marketing Officer, effective April 27, 2026. Manso will lead the company's integrated marketing organization, focusing on consumer engagement and personalized health experiences. His role aims to strengthen Haleon's marketing capabilities in response to evolving consumer expectations in health management.
Read more →HLNHALEON APPOINTS CARL HANEY AS CHIEF R&D OFFICER
Haleon has appointed Carl Haney as Chief Research & Development Officer, effective August 1, 2025. Haney, who previously worked at Estée Lauder and P&G, replaces Franck Riot, who is leaving after six years. CEO Brian McNamara expressed confidence in Haney's ability to drive innovation and contribute to Haleon's growth strategy.
Read more →HLNPoligrip & Polident Showcases Impact of Receiving Dentures in New Video and Launches Second Nationwide Oral Health and Wellness Tour with Free Dental Care to those in Underserved Communities
WARREN, N.J., March 20, 2025 /PRNewswire/ -- On World Oral Health Day, Polident and Poligrip, the World's #1 Denture Care Brand1, and Remote Area Medical (RAM) Volunteer Corp, are excited to announce the release of a new video showcasing the transformative impact of dentures on p
Read more →HLNHaleon Welcomes Joe Sta-Romana as Chief Customer Officer to Lead US Growth and Transformation
Haleon has appointed Joe Sta-Romana as Chief Customer Officer for its U.S. operations, effective December 1, 2024. With over 20 years of experience in the FMCG sector, he will lead customer strategy and drive growth. His military background and leadership at Unilever will support Haleon's transformation and customer-focused initiatives.
Read more →HLNHaleon Announces the Launch of Eroxon®, The First and Only FDA Cleared OTC Gel for Erectile Dysfunction, Available for U.S. Preorder Without a Prescription
Haleon has launched Eroxon®, the first FDA cleared over-the-counter gel for erectile dysfunction, available for pre-order in the U.S. The gel is clinically proven to help men achieve an erection within 10 minutes, significantly faster than existing prescription treatments. Eroxon aims to enhance intimacy for men affected by erectile dysfunction, addressing a critical health need.
Read more →HLNNew Research Affirms the Positive Impact of Centrum Silver on Memory in Older Adults
Recent findings from the COSMOS-Clinic study reinforce the positive effects of Centrum Silver on memory in older adults. This study is the third in a series that consistently shows significant improvements in cognitive function when compared to a placebo. With over 5,000 participants across all studies, the results highlight the importance of daily multivitamin intake for cognitive health. Centrum continues to lead in nutritional research, supporting ongoing studies in this area.
Read more →HLNHaleon Issues Voluntary Nationwide Recall of Robitussin Honey CF Max Day Adult and Robitussin Honey CF Max Nighttime Adult Products Due to Microbial Contamination
WARREN, N.J., Jan. 24, 2024 /PRNewswire/ -- Haleon is voluntarily recalling eight lots of Robitussin Honey CF Max Day Adult and Robitussin Honey CF Max Nighttime Adult to the consumer level. The product is being recalled due to microbial contamination. Robitussin Honey CF Max Da
Read more →HLNVoltaren Partners with Fitness Instructor and TV Personality Amanda Kloots to Help Caregivers Discover the Joy of Movement
Leader in joint pain relief stands with caregivers help recognize their value and provide pain relief and movement resources. WARREN, N.J., May 16, 2023 /PRNewswire/ -- More than 53 million Americans provide care to family members or loved ones,1 but an overwhelming 4 out of 5 A
Read more →HLNHaleon launches with purpose to deliver better everyday health with humanity
Maker of Sensodyne, Advil, and TUMS becomes one of the world's leading independent consumer health companies Demerger from GSK plc (GSK) now complete WARREN, N.J., July 18, 2022 /PRNewswire/ -- Today, Haleon (LSE/NYSE: HLN) launches as an independent company 100% focused on con
Read more →HLNFDA approves GSK's Advil Dual Action with Acetaminophen for over-the-counter use in the United States
The FDA has approved GSK's Advil Dual Action with Acetaminophen for over-the-counter use, marking it as the first OTC combination of ibuprofen and acetaminophen in the U.S. This product aims to provide effective pain relief for various conditions.
Read more →HLNFDA approves GSK's Voltaren Arthritis Pain for over-the-counter use in the United States
The FDA has approved GSK's Voltaren Arthritis Pain as an over-the-counter product for arthritis pain relief, making it the first prescription strength NSAID topical gel available OTC in the U.S. This approval aims to provide nearly 30 million Americans with easier access to effective pain relief.
Read more →HLNFDA Approves FLONASE® Sensimist™ Allergy Relief
The FDA has approved FLONASE Sensimist as an over-the-counter treatment for allergy symptoms, offering 24-hour relief. This product, previously available by prescription, aims to meet the needs of allergy sufferers and will be available nationally in early 2017.
Read more →HLNFDA Approves Flonase® Allergy Relief For Sale Over-The-Counter In The United States
The FDA has approved Flonase® Allergy Relief for over-the-counter sale, making it the first OTC nasal spray for comprehensive allergy symptom relief. This approval aims to provide effective treatment for the 50 million Americans suffering from nasal allergies.
Read more →About Haleon plc
BIOPHARMAWATCH ELITE PLUS
Trade the next HLN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime